Scrip

Lupin has followed Sandoz and Sun Pharma in settling antitrust litigation with US insurance giant Humana on alleged price-fixing. This $30m settlement denies all allegations and does not imply admission of liability, but could more settlements follow?

Storm Therapeutics, a company targeting novel cancer therapies to target RNA modifications and reprogram cells, has announced a $56m series C financing. The proceeds will support the advancement of STC-15, a first‑in‑class, oral small-molecule inhibitor of METTL3. The first patient has been...

Scrip >>Leadership >>Executive Moves Executives On The Move: Ailux Gets A New CSO From AstraZeneca Recent changes in the industry include board appointments at Avalyn Pharma, Faron Pharmaceuticals and Telix Pharmaceuticals, plus a raft of new appointments at Ambrose Healthcare include a new chief of intellectual property from GSK.

Global Investors Provide 30% Of New Funding South Korean biotech’s successful funding buoyed by strong global investor interest and encouraging Phase II data for MASH contender DD01.

Erasca led a group of specialist oncology companies gaining ground in the first quarter of 2026, while companies developing novel obesity assets have experienced the downside of yo-yoing investor sentiment. (Shutterstock) Mid-cap listed biopharma companies often see big swings in their valuations, and the first quarter of 2026 was no exception. Market data compiled by Evaluate captured these movements from January to the end of March, showing the ten mid-cap firms...

Multiple First-In-Class Pipeline Assets On the heels of Alphamab Oncology's anti-HER2 bispecific meeting its Phase III endpoint in early breast cancer, the Chinese firm's CEO shares pipeline development plans and R&D strategies.

What: Obsidian will go public by reverse merging with troubled Galera, which had planned to liquidate its assets following an...

Entries are now open for the 22nd Annual Scrip Awards Firmly established as best in class for pharma and biotech, the Scrip Awards will be held on Wednesday, Dec. 2, 2026, at the historic venue Raffles London at The OWO. Since their inception, the Scrip Awards has proudly celebrated the essential role the pharmaceutical, biotech and allied industries play in advancing healthcare.

If approved, the combination of darovasertib and crizotinib would be the first therapy for patients with HLA-A2*02:01-negative metastatic uveal melanoma. Ideaya's combo regimen for uveal melanoma may be ready for an FDA filing • Source: Shutterstock Key Takeaways Ideaya and Servier reported positive Phase II/III data in a subset of uveal melanoma patients that they believe will provide the basis for accelerated approval from the FDA.

Gears Up For Stock Listing This Year The Korean bioventure’s oversubscribed pre-IPO financing followed a $1bn global licensing deal with Sanofi and is set to support a planned KOSDAQ listing by the end of this year. Investors Express Strong Interest And Firm Intent To Invest (Shutterstock) South Korea’s ADEL has raised a higher-than-expected KRW49bn ($33.1m) in a pre-IPO financing round that it will use to further progress the development of its neurodegenerative disease assets.